PainResearch Phase

Deltorphin

Intracerebroventricular, Subcutaneous injection

Overview

Deltorphin is a heptapeptide opioid agonist also derived from Phyllomedusa frog skin secretions, characterized by high selectivity for delta-opioid receptors. Like dermorphin, it contains an unusual D-amino acid residue that enhances metabolic stability and receptor affinity.

Mechanism of Action

Deltorphin exhibits analgesic properties distinct from mu-opioid agonists, with reduced respiratory depression and addiction liability in animal models. It has served as a pharmacological tool to elucidate delta-opioid receptor physiology and potential therapeutic roles..

Research Summary & Key Findings

Animal studies have shown potent antinociceptive effects with a more favorable side effect profile compared to morphine, particularly regarding respiratory suppression. Deltorphin analogs have been investigated to develop more stable and blood-brain barrier permeable compounds. Clinical translation has not occurred, and current use is limited to preclinical research applications.

Clinical Status

Research Phase

Deltorphin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

IntracerebroventricularSubcutaneous injection

Related Peptides in Pain

Find a Provider

Find a verified provider who offers Deltorphin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Deltorphin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.